These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7537599)

  • 61. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The effectiveness of beta-sitosterol in treatment of benign prostatic hyperplasia].
    Senge T; Windeler J; Berges RR; Trampisch HJ
    Urologe A; 1995 Mar; 34(2):130-1. PubMed ID: 7538710
    [No Abstract]   [Full Text] [Related]  

  • 63. Effect of alfuzosin on female primary bladder neck obstruction.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Perimenis P
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):217-22. PubMed ID: 18982236
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 66. Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity?
    Chapple CR
    Br J Urol; 1995 Jul; 76 Suppl 1():47-55. PubMed ID: 7544214
    [No Abstract]   [Full Text] [Related]  

  • 67. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.
    Altan-Yaycioglu R; Yaycioglu O; Gul U; Pelit A; Adibelli FM; Akova YA
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):199-203. PubMed ID: 17394035
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials.
    Kortmann BB; Floratos DL; Kiemeney LA; Wijkstra H; de la Rosette JJ
    Urology; 2003 Jul; 62(1):1-9. PubMed ID: 12837408
    [No Abstract]   [Full Text] [Related]  

  • 71. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Clinical aspects of benign prostatic hypertrophy].
    Pisani E; Montanari E; Trinchieri A
    J Urol (Paris); 1993; 99(6):288-9. PubMed ID: 7516368
    [No Abstract]   [Full Text] [Related]  

  • 75. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
    Hansen BJ; Flyger H; Mortensen S; Mensink HJ; Meyhoff HH
    Scand J Urol Nephrol; 1996 Apr; 30(2):103-7. PubMed ID: 8738054
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Kuczyk MA; Herrmann TR
    Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bunazosin. Andante, Detantol, E 1015, E 643, EA 0643.
    Drugs R D; 1999 Dec; 2(6):417-9. PubMed ID: 10763455
    [No Abstract]   [Full Text] [Related]  

  • 78. The assessment of medical treatment for benign prostatic hyperplasia (BPH).
    Roehrborn CG
    Prog Clin Biol Res; 1994; 386():175-90. PubMed ID: 7528385
    [No Abstract]   [Full Text] [Related]  

  • 79. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
    Roehrborn CG
    Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.